Ataibeckley INC

Eli Lilly and Company announced a definitive agreement to acquire AtaiBeckley Inc. for $6.75 per share in cash plus a contingent value right (CVR) for potential future payments.

AtaiBeckley Inc. has entered into a merger agreement with Eli Lilly and Company for an acquisition valued at $6.75 per share plus contingent value rights, while reporting Q2 2026 results with increased R&D expenses and continued net losses.

Atai Life Sciences Director Robert Hershberg executed a Rule 10b5-1 trading plan, involving the exercise of stock options and sale of common stock.

AtaiBeckley Inc. announces a merger agreement with Eli Lilly and Company, with key shareholders Apeiron Investment Group Ltd. and Christian Angermayer entering into voting and support agreements.